CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
← catalyst calendarSponsored by Cullinan Therapeutics Inc. (industry) · CGEM — their whole pipeline →.
Phase
Phase 1
Status
Terminated
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
23actual
Sites
5
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Company decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-12-12 | actual | When the study began enrolling |
| Primary completion | 2026-06-16 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-16 | actual | The whole study's end, after follow-up |
| First posted | 2023-09-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumor
Interventions
- Drug: CLN-617
- Drug: Pembrolizumab — also filed as Keytruda
Primary outcomes
what the primary-completion date above is the date OFDose Escalation
measured 24 Months
Dose Optimization
measured 24 Months
Dose Expansion
measured 24 Months
Dose Expansion
measured 24 Months
Dose Expansion
measured 24 Months
Dose Expansion
measured 24 Months
Dose Expansion
measured 24 Months
Publications
- PMID 38842347 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · CGEM's whole pipeline · Catalyst calendar · Every registered study · What changed